drugset / Trial / NCT05309187
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).
Timeline
- Start
- 2022-04-11
- Primary completion
- 2024-03-29
- Completion
- 2024-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IO-202 | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |